160 related articles for article (PubMed ID: 2697430)
1. Graft-versus-host disease: effects on long term disease free survival in marrow transplantation for haematological malignancies.
Kapoor N; Copelan EA; Klein J; Tutschka PJ
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():153-5. PubMed ID: 2697430
[No Abstract] [Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Przepiorka D; Ippoliti C; Giralt S; van Beisen K; Mehra R; Deisseroth AB; Andersson B; Luna M; Cork A; Lee M
Bone Marrow Transplant; 1994 Sep; 14(3):449-53. PubMed ID: 7994271
[TBL] [Abstract][Full Text] [Related]
5. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
6. Treatment of leukemia by marrow transplantation from HLA incompatible donors. Effect of HLA-disparity on GVHD, relapse and survival.
Hansen JA; Anasetti C; Beatty PG; Martin PJ; Sanders JE; Storb R; Thomas ED
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():108-11. PubMed ID: 2390636
[No Abstract] [Full Text] [Related]
7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
8. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic bone marrow transplantation for ALL in Zagreb.
Bogdanić V; Labar B; Nemet D; Mrsić M; Pavetić Z; Aurer I
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():88-9. PubMed ID: 2697414
[No Abstract] [Full Text] [Related]
10. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
Arch Immunol Ther Exp (Warsz); 1991; 39(4):441-7. PubMed ID: 1821620
[No Abstract] [Full Text] [Related]
11. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Copelan EA; Penza SL; Elder PJ; Belt PS; Scholl MD; Hehmeyer DM; Ezzone SA; Bechtel TP; Avalos BR
Bone Marrow Transplant; 1996 Nov; 18(5):907-11. PubMed ID: 8932844
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Mrsić M; Nemet D; Labar B; Bogdanić V; Radman I; Zupancić-Salek S; Kovacević-Metelko J; Aurer I; Maravić N
Transplant Proc; 1993 Feb; 25(1 Pt 2):1268-70. PubMed ID: 8442109
[No Abstract] [Full Text] [Related]
13. Bone marrow transplantation and graft-versus-host disease.
Powles RL
Curr Opin Immunol; 1989-1990; 2(6):870-5. PubMed ID: 2486567
[No Abstract] [Full Text] [Related]
14. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
17. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
[TBL] [Abstract][Full Text] [Related]
19. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.
Rizzoli V; Carella AM; Carlo-Stella C; Mangoni L
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():76-8. PubMed ID: 2202474
[No Abstract] [Full Text] [Related]
20. Allogeneic BMT for AML in Zagreb.
Labar B; Bogdanić V; Nemet D; Mrsić M; Pavletić Z; Zupancić S; Radman I; Aurer I
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():86-7. PubMed ID: 2697413
[No Abstract] [Full Text] [Related]
[Next] [New Search]